Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 11/20 | 0.53 |
| ▸ | SYK | P43405 | 8/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4297215 | 0.93 | MAPKAPK5 (0.45) | MAPKAPK5SYKTTKEML4ALK | |
| SCHEMBL1570213 | 0.88 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTKEML4ALK | |
| SCHEMBL1476062 | 0.87 | MAPKAPK5 (0.60) | MAPKAPK5SYK | |
| SCHEMBL1570061 | 0.87 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTK | |
| SCHEMBL1570261 | 0.86 | MAPKAPK5 (0.70) | MAPKAPK5TTK | |
| Glpg-0259 SCHEMBL12661679 | 0.84 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTK | |
| Glpg-0259 SCHEMBL1570157 | 0.84 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTK | |
| Glpg-0259 SCHEMBL1889564 | 0.84 | MAPKAPK5 (0.49) | MAPKAPK5SYKTTK | |
| SCHEMBL1476692 | 0.84 | MAPKAPK5 (0.73) | MAPKAPK5SYK | |
| SCHEMBL12443292 | 0.83 | MAPKAPK5 (0.65) | MAPKAPK5SYKEML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307426-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-04-13 | — | — | EP | claimed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | claimed |
| WO-2009135885-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-12 | — | — | WO | claimed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| US-8012983-B2 | Substituted triazolopyrazines useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-09-06 | — | — | US | disclosed |
| EP-2307426-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | Galapagos N.V. (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-19 | — | — | US | disclosed |
| WO-2009135885-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286798-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | IL1B, IL1A, PTGER1 | MAPKAPK5 131/4885SYK 3339/4885TTK 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.